Not yet recruiting
Study of Cadonilimab (AK104) Plus Eribulin vs. Eribulin Monotherapy for Recurrent or Metastatic Triple-negative Breast Cancer
NCT06202313
- Conditions
- Breast Diseases, Breast Neoplasms, Neoplasms, +5 more
- Locations
-
- Shengjing Hospital of China Medical University Shenyang, Liaoning, China